The business challenges facing health-tech companies as they ccale across borders

Scaling a health-tech company internationally becomes easier to manage when legal, technical and commercial planning begin before market entry

ARE YOU SCALING a health-tech company internationally? Each new market brings distinct regulations, healthcare systems and commercial expectations that can quickly turn promising expansion into an expensive compliance exercise.

Here are the key business challenges you need to be aware of as you scale across borders.

Navigating Regulatory Fragmentation

Regulatory approval in one country rarely guarantees approval elsewhere. Requirements can vary according to product classification, clinical purpose, risk level and the way patient data are processed.

For example, there are ongoing efforts to harmonise international medical-device regulation. Companies must still manage country-specific submissions, quality-management standards, labelling rules and post-market monitoring while keeping product development moving.

Managing Data Across Multiple Jurisdictions

Entering another jurisdiction can change where health data may be stored, transferred and accessed. Consent requirements, retention periods and rules covering secondary research may also differ, forcing companies to redesign established data workflows.

Specialist healthcare and life sciences lawyers can help businesses navigate things like privacy laws, clinical trial agreements, FDA and ISO compliance and multi-jurisdictional regulatory matters.

Defending a Growing Digital Footprint

International growth creates more integrations, users, devices and third-party suppliers. Every new connection can expand the company’s cyberattack surface while making incident reporting more complicated.

Research from ENISA found that 45% of the health-sector incidents analysed in its 2024 threat landscape involved ransomware. Health-tech leaders therefore need security controls that work across the entire organisation, rather than separate protections added after each market launch.

Finding Sustainable Reimbursement Routes

Regulatory clearance does not ensure that hospitals, insurers or public health systems will pay for a product. Reimbursement pathways differ widely, with each market applying its own evidence standards, assessment processes and pricing expectations.

Open-access digital-health policy research identifies regulation, value assessment, pricing and patient-access infrastructure as key parts of market entry.

Local clinical evidence may be needed even when a solution has performed well elsewhere, increasing costs and delaying revenue.

Adapting Products to Local Health Systems

A technically sound product may still fail if it does not fit local clinical routines. Products often need to integrate with different electronic health records, languages, accessibility requirements and professional practices.

Teams must balance localisation with product consistency. Excessive customisation raises maintenance costs, yet insufficient adaptation can reduce clinician trust, patient engagement and adoption.

Local partnerships can help companies understand how clinicians and patients use technology in practice. Early feedback from healthcare providers can reveal workflow barriers before they become costly problems.

In turn, products can remain consistent while meeting genuine local needs.

Sustainable Growth for Health-Tech Companies

The business challenges facing health-tech companies become easier to manage when legal, technical and commercial planning begin before market entry. Assess regulatory obligations, data flows, reimbursement options and integration needs as one connected expansion strategy.

You should now be aware of the challenges your health-tech company may face when expanding internationally. But make sure you delve deeper before you proceed across borders. And if this article has been helpful, check out some of our related content.